Sangamo Therapeutics Inc. Common Stock (SGMO)

FairStock Score: 21/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable competitive advantages, honest accounting, and a margin of safety. Sangamo offers none of these today. It is a clinical-stage genomic medicine company with 142 employees and no approved products, so its economic moat is unproven and likely depends entirely on patents and trial outcomes. The financials are grim. In the first quarter of fiscal 2026, revenue was $1.4 million and net income was negative $31.0 million, a margin of -2149.45%. Trailing free cash flow was negative $90.5 million, giving a FairStock-calculated FCF yield of -88.0% against the $102.8 million market cap at the close on 2026-07-02. The FairStock-calculated P/E is -0.19, ROE is -2891.84%, and ROCE is -94.37%. The Piotroski F-Score is 3/9 and Altman Z-Score is -39.99, both signaling severe financial distress. The data show revenue growth of 88.43% and profit growth of -59.94%, though the periods are not specified in the provided data. The stock trades at $0.07, near the low end of its 52-week range of $0.06 to $0.70, but a low price is not a bargain when the business loses money and consumes cash. Graham would demand assets or earnings; neither is evident. Buffett would ask for a moat and pricing power; Sangamo has neither yet. FairStock assigns no Lynch category because there are zero years of filed annual results, needing three. Until the pipeline produces commercial success or the cash burn stops, this remains a speculative clinical-stage venture, not a value investment.

In plain English: Sangamo Therapeutics is a clinical-stage gene therapy company trying to develop treatments for serious diseases like Fabry disease and neuropathic pain. The business is not profitable and is burning cash, with very little revenue and large losses. The stock price is extremely low, but the numbers do not show a strong or stable business, so it is not clearly cheap on fundamentals.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-07-02 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer